A detailed history of Acadian Asset Management LLC transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 1,954,198 shares of KOD stock, worth $19.3 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,954,198
Previous 1,965,449 0.57%
Holding current value
$19.3 Million
Previous $4.61 Million 10.42%
% of portfolio
0.02%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$2.2 - $3.25 $24,752 - $36,565
-11,251 Reduced 0.57%
1,954,198 $5.1 Million
Q2 2024

Aug 06, 2024

BUY
$2.29 - $4.48 $555,460 - $1.09 Million
242,559 Added 14.08%
1,965,449 $4.61 Million
Q1 2024

May 10, 2024

SELL
$3.01 - $7.45 $558,090 - $1.38 Million
-185,412 Reduced 9.72%
1,722,890 $9.06 Million
Q4 2023

Feb 13, 2024

BUY
$1.4 - $3.24 $380,353 - $880,246
271,681 Added 16.6%
1,908,302 $5.8 Million
Q3 2023

Nov 13, 2023

BUY
$1.8 - $7.49 $2.11 Million - $8.79 Million
1,173,832 Added 253.64%
1,636,621 $2.95 Million
Q2 2023

Aug 07, 2023

SELL
$4.3 - $9.48 $1.03 Million - $2.26 Million
-238,833 Reduced 34.04%
462,789 $3.19 Million
Q1 2023

May 11, 2023

SELL
$4.81 - $8.88 $140,466 - $259,322
-29,203 Reduced 4.0%
701,622 $4.35 Million
Q4 2022

Feb 14, 2023

BUY
$6.52 - $8.05 $776,238 - $958,392
119,055 Added 19.46%
730,825 $5.23 Million
Q3 2022

Nov 14, 2022

BUY
$7.57 - $12.5 $617,689 - $1.02 Million
81,597 Added 15.39%
611,770 $4.74 Million
Q2 2022

Aug 09, 2022

BUY
$5.04 - $9.48 $317,565 - $597,325
63,009 Added 13.49%
530,173 $4.05 Million
Q1 2022

May 12, 2022

BUY
$7.09 - $89.45 $3.31 Million - $41.8 Million
467,164 New
467,164 $3.6 Million

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $514M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.